We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • Topics
  • Nutra-Q Directory
  • Magazine
  • e-Learning Tools
  • Advertise

Modern Medicine Network
  • Login
  • Register
Skip to main content
  • Login
  • Register
Menu
User
Home
  • Topics
  • Nutra-Q Directory
  • Magazine
  • e-Learning Tools
  • Advertise

SUBSCRIBE: eNewsletter | Magazine

NattoPharma’s Research Network Receives €4M EU Grant to Fund Research on Vitamin K2 and Vascular Health

  • Photo © iStockphoto.com/jasminam
  • Jennifer Grebow
Apr 17, 2017
  • Heart Health, Science

NattoPharma (Oslo, Norway), supplier of the branded MenaQ7 vitamin K2 ingredient, announced that the company’s NattoPharma International Research Network has received a €4 million grant from the European Commission’s research program, Horizon 2020, to study vitamin K2’s role in vascular health.

“Horizon 2020 grants are the European equivalent to a National Institutes of Health (NIH) grant here in the United States,” said NattoPharma’s chief medical officer, Hogne Vik, in a press release.

According to NattoPharma, this funding “will provide training in innovative therapeutic strategies that include MenaQ7, identifying selective targets for microvascular calcification, and its consequences for plaque stability, and provide subsequent strategies for prevention or amelioration of vulnerable plaque formation.”

The NattoPharma International Research Network is coordinated by the Cardiovascular Research Institute at Maastrich University (CARIM). The grant, named INTRICARE, or “International Network for Training on Risks of Vascular Intimal Calcification and Roads to Regression of Cardiovascular Disease,” will fund a consortium made up of three highly ranked research university departments—CARIM, Universitätsklinikum Aachen, Karolinska Institutet Stockholm, and King’s College London—as well as 9 small- and medium-sized enterprises, including NattoPharma.

Related Articles

  • Lipid-Encapsulated Curcumin Provides Greater Anti-Inflammatory, Neuroprotective Benefits than Unformulated Curcumin in Animal Study
  • Joint-Health Botanical Extract Blend Reduced Muscle Soreness, Supported Exercise Recovery, in New Study, Company Says
  • UC-II Collagen Reduces Cartilage Deterioration in Animal Study
  • Mung Bean Protein Isolate May Improve Insulin Response, Reduce Fat Accumulation
  • Phospholipid Ingredient Blend Reduces PMS Symptoms in New Study

Fun Facts

Fun Fact!

Weekly Fun Facts about nutrition and ingredients, courtesy of Nutritional Outlook's editors

Current Issue

Nutritional Outlook Vol. 21, No 3
Apr 01, 2018 Vol 21 No 3
Digital Edition
Connect with Us
  • Twitter
  • Facebook
  • Google+
  • LinkedIn
  • RSS
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.